Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Increased by Brookstone Capital Management

Brookstone Capital Management boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 751.1% during the 1st quarter, HoldingsChannel reports. The firm owned 127,258 shares of the biopharmaceutical company’s stock after buying an additional 112,305 shares during the quarter. Brookstone Capital Management’s holdings in Gilead Sciences were worth $9,322,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the company. Tompkins Financial Corp raised its position in shares of Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares in the last quarter. Private Wealth Management Group LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $29,000. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $29,000. Sachetta LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $30,000. Finally, Rakuten Securities Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $33,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

GILD stock opened at $68.83 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $85.75 billion, a price-to-earnings ratio of 191.19, a P/E/G ratio of 2.95 and a beta of 0.20. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86. The firm has a 50 day moving average of $65.89 and a two-hundred day moving average of $72.75.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.37 earnings per share. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.47%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s dividend payout ratio is 855.56%.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on GILD shares. Maxim Group dropped their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Barclays dropped their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a report on Monday, April 29th. Royal Bank of Canada reissued a “sector perform” rating and issued a $74.00 target price on shares of Gilead Sciences in a research report on Friday, June 14th. Finally, Oppenheimer reissued an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. Twelve analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $83.47.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.